arrow
M

Mark F. Cotton

Tygerberg Hospital
H指数:47
被引数:9,558

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetics of Efavirenz in Pregnancy and Postpartum with and Without First-line Tuberculosis Drugs: Results from IMPAACT P1026s

妊娠及产后期间使用和不使用一线结核病药物时依非韦伦的药代动力学:IMPAACT P1026s研究结果

2026-10-030
OA
VRC01 with antiretroviral initiation in infants is well tolerated; and higher concentrations associate with greater HIV-1 DNA declines

婴儿期抗逆转录病毒启动的VRC01耐受性良好;较高浓度与更大的HIV-1 DNA下降相关

2026-05-060
PRE
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial

达olutegravir分散片和口服薄膜在暴露于HIV的南非足月新生儿中的安全性与药代动力学(PETITE-DTG研究):一项开放标签、随机、1/2期试验

2025-10-080
PRE
ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study

ART-free HIV-1 remission in儿童 with宫内HIV-1感染 after very early ART (IMPAACT P1115):一项多中心、开放标签、Ⅰ/Ⅱ期概念验证研究

2025-09-250
PRE
Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries
2024-10-281
OAAI
High mortality following early initiation of antiretroviral

早期开始抗逆转录病毒治疗后死亡率高

2024-07-013
OAAI
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study
2024-01-015
OAAI
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s
2023-11-155
OA
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically- suppressed children and adolescents living with HIV-Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
2023-06-014
OAAI